These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36933492)

  • 41. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.
    Xu XS; Qu K; Liu C; Zhang YL; Liu J; Song YZ; Zhang P; Liu SN; Chang HL
    World J Gastroenterol; 2012 Dec; 18(48):7242-50. PubMed ID: 23326129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 44. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
    Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
    Front Oncol; 2022; 12():962173. PubMed ID: 36059629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.
    Zhang R; Zhao H; Wang P; Guo Z; Liu C; Qu Z
    BMC Cancer; 2023 Dec; 23(1):1181. PubMed ID: 38041022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters.
    Jia G; Qiu L; Zheng H; Qin B; Sun Z; Shao Y; Yang Z; Shao J; Zhou Y; Jiao S
    BMC Cancer; 2023 Jun; 23(1):556. PubMed ID: 37328805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.
    Park H; Kim SU; Park JY; Kim DY; Ahn SH; Chon CY; Han KH; Seong J
    Liver Int; 2014 Feb; 34(2):313-21. PubMed ID: 23895043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee CJ; Lee IC; Chen SC; Hou MC; Huang YH
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors.
    Wan L; Wu C; Luo S; Xie X
    Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Rugambwa TK; Abdihamid O; Zhang X; Peng Y; Cai C; Shen H; Zeng S; Qiu W
    Front Oncol; 2023; 13():1181248. PubMed ID: 38023176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China.
    Chi X; Jiang L; Yuan Y; Huang X; Yang X; Hochwald S; Liu J; Huang H
    BMC Gastroenterol; 2022 Apr; 22(1):202. PubMed ID: 35461226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
    Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
    World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
    Front Immunol; 2022; 13():827788. PubMed ID: 35211122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
    Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
    Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
    Liu J; Wu Q; Wu S; Xie X
    Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.